Sector: MedicalAmylin Pharmaceuticals, Inc. (NASDAQ: AMLN)
Headlines
- Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
Nov 05, 2009 04:15 PM | AMLN
- LILLY (ELI) & COMPANY - STATEMENT ON FDA'S BYETTA (EXENATIDE) INJECTION UPDATE
Nov 03, 2009 02:02 AM | AMLN, LLY
- Innovative Drug Companies Headline The Gainers
Nov 02, 2009 04:49 PM | AMLN, HGSI, VRTX
- PicksThatMove.com Announces Investment Opinion On: Human Genome Science Inc., General Electric Company, eBay Inc., NovaDel Pharma Inc., and Amylin Pharmaceuticals Inc.
Nov 02, 2009 04:23 PM | AMLN, EBAY, GE, NVD
- Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDA's BYETTA(R) (Exenatide) Injection Update
Nov 02, 2009 03:30 PM | AMLN, LLY
- Dr. Stockpick Announces Daily Stock Watch - AMLN, VRTX, HGSI
Nov 02, 2009 09:40 AM | AMLN, HGSI, VRTX
- Amylin Pharmaceuticals and Takeda Enter into Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity
Nov 01, 2009 06:30 PM | AMLN
- BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes
Oct 30, 2009 08:17 PM | AMLN, LLY
- Amylin Pharmaceuticals Reports Third Quarter Financial Results
Oct 20, 2009 04:05 PM | AMLN
- Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
Oct 19, 2009 04:15 PM | AMLN
- FDA: Byetta drug label is revised
Nov 02, 2009 04:05 PM | AMLN
- Domain Raises $500M Life Sciences Fund
Aug 11, 2009 03:57 PM | AMLN, CADX, OREX, SNTS, VOLC
- Amylin Pharmaceuticals Q2 Net Loss Narrows
Jul 27, 2009 06:51 AM | AMLN
- Citigroup, Wells Fargo, Boeing are big movers
Jan 28, 2009 06:23 PM | AAI, AMLN, BA, C, COP, GD
- Why Clean Tech Is Taking Biotech's Shine
Oct 07, 2008 10:53 AM | AMLN, ARNA, SGP, SNMX
- Amylin Pharmaceuticals Board of Directors Elects Paulo F. Costa Chairman of the Board
Aug 24, 2009 07:45 AM | AMLN
- Amylin Pharmaceuticals Reports Second Quarter Financial Results
Jul 21, 2009 04:06 PM | AMLN
- Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus(R) in Head-to-Head DURATION-3 Study
Jul 20, 2009 04:15 PM | ALKS, AMLN, LLY
- Amylin Pharmaceuticals to Webcast Second Quarter Results
Jul 14, 2009 04:06 PM | AMLN
- Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity
Jul 09, 2009 07:45 AM | AMLN
- New Drug Application for Exenatide Once Weekly Accepted for Review by FDA
Jul 07, 2009 04:05 PM | ALKS, AMLN, LLY
- Amylin Pharmaceuticals to Present at Piper Jaffray Europe Conference
Jun 17, 2009 04:16 PM | AMLN
- Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009
Jun 08, 2009 06:45 PM | AMLN, LLY
- Interim Study Results Presented at ADA 2009: Exenatide Not Associated With Increased Rate of Acute Pancreatitis Compared to Other Antidiabetic Drugs
Jun 07, 2009 09:00 AM | AMLN, LLY
- Use of Mealtime Pramlintide Added to Basal Insulin Showed Similar Improvements in Glycemic Control Compared to Rapid-Acting Insulin, With Lower Risk of Hypoglycemia and Without Weight Gain: Data Presented at ADA 2009
Jun 06, 2009 06:30 PM | AMLN
- Form 4 AMYLIN PHARMACEUTICALS For: Oct 02 Filed by: SULLIVAN JOSEPH P (10K)
Oct 06, 2009 08:22 PM
- Form 4 CLARK PAUL N For: Oct 02 (10K)
Oct 06, 2009 08:22 PM
- Form 4 BECK TERESA For: Oct 02 (10K)
Oct 06, 2009 08:22 PM
- Form 4 ALTMAN STEVEN R For: Oct 02 (10K)
Oct 06, 2009 08:21 PM
- Form 4 GAVIN JAMES R III For: Oct 02 (10K)
Oct 06, 2009 08:21 PM
- Form 4 EASTHAM KARIN For: Oct 02 (10K)
Oct 06, 2009 08:21 PM
- Form 4 AMYLIN PHARMACEUTICALS For: Sep 16 Filed by: EASTBOURNE CAPITAL MANAGEMENT LLC/CA (10K)
Sep 18, 2009 06:02 PM
- Form 4 Denner Alexander J For: Jun 09 (10K)
Jun 11, 2009 05:12 PM
- Form 3 Denner Alexander J For: Jun 09 (10K)
Jun 11, 2009 05:11 PM
- Form 4 ADAMS ADRIAN For: May 27 (10K)
Jun 11, 2009 01:00 PM
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
AMLN
|
Compare to S&P
|
| YTD |
1.75 %
|
-11.30 %
|
| 4 Weeks |
-15.21 %
|
-16.11 %
|
| 12 Weeks |
-25.46 %
|
-27.31 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 47.22 %
|
|
EPS Growth in Last Year: 58.70 %
|
|
Sales Growth in Last Quarter: 0.89 %
|
|
Sales Growth in Last Quarter: -3.26 %
|
|
